138 related articles for article (PubMed ID: 12869082)
21. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Labenz J; Blum AL; Bolten WW; Dragosics B; Rösch W; Stolte M; Koelz HR
Gut; 2002 Sep; 51(3):329-35. PubMed ID: 12171952
[TBL] [Abstract][Full Text] [Related]
22. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.
Zabinski RA; Burke TA; Johnson J; Lavoie F; Fitzsimon C; Tretiak R; Chancellor JV
Pharmacoeconomics; 2001; 19 Suppl 1():49-58. PubMed ID: 11280105
[TBL] [Abstract][Full Text] [Related]
23. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Chan FK; To KF; Wu JC; Yung MY; Leung WK; Kwok T; Hui Y; Chan HL; Chan CS; Hui E; Woo J; Sung JJ
Lancet; 2002 Jan; 359(9300):9-13. PubMed ID: 11809180
[TBL] [Abstract][Full Text] [Related]
24. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.
Ashcroft DM; Chapman SR; Clark WK; Millson DS
Ann Pharmacother; 2001; 35(7-8):829-34. PubMed ID: 11485128
[TBL] [Abstract][Full Text] [Related]
25. Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis.
Crilly MA; Mangoni AA; Knights KM
Clin Exp Rheumatol; 2013; 31(5):691-8. PubMed ID: 23899748
[TBL] [Abstract][Full Text] [Related]
26. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study.
Chan FK; Sung JJ; Suen R; Lee YT; Wu JC; Leung WK; Chan HL; Lai AC; Lau JY; Ng EK; Chung SC
Aliment Pharmacol Ther; 1998 Dec; 12(12):1201-5. PubMed ID: 9882027
[TBL] [Abstract][Full Text] [Related]
27. NSAIDs, Helicobacter pylori, and Pandora's Box.
Graham DY
N Engl J Med; 2002 Dec; 347(26):2162-4. PubMed ID: 12501230
[No Abstract] [Full Text] [Related]
28. Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Peura D; Chan FK; Wilcox CM; Niculescu L; Berger M
Gastroenterology; 2008 Jan; 134(1):370-1; author reply 371. PubMed ID: 18166374
[No Abstract] [Full Text] [Related]
29. Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
Goldstein JL; Chan FK; Lanas A; Wilcox CM; Peura D; Sands GH; Berger MF; Nguyen H; Scheiman JM
Aliment Pharmacol Ther; 2011 Oct; 34(7):808-16. PubMed ID: 21810115
[TBL] [Abstract][Full Text] [Related]
30. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
31. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
Al MJ; Michel BC; Rutten FF
Pharmacoeconomics; 1996 Aug; 10(2):141-51. PubMed ID: 10163417
[TBL] [Abstract][Full Text] [Related]
32. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
[TBL] [Abstract][Full Text] [Related]
33. COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Cryer B
Gastroenterology; 2004 Oct; 127(4):1256-8. PubMed ID: 15481002
[No Abstract] [Full Text] [Related]
34. [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Soto Alvarez J
An Med Interna; 2000 Sep; 17(9):477-84. PubMed ID: 11100534
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
36. Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial.
Kellner HL; Li C; Essex MN
Open Rheumatol J; 2013; 7():96-100. PubMed ID: 24358067
[TBL] [Abstract][Full Text] [Related]
37. Omeprazole and misoprostol for preventing gastric mucosa effects caused by indomethacin and celecoxib in rats.
Cavallini ME; Andreollo NA; Metze K; Araújo MR
Acta Cir Bras; 2006; 21(3):168-76. PubMed ID: 16751931
[TBL] [Abstract][Full Text] [Related]
38. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
Bianchi Porro G; Parente F; Imbesi V; Montrone F; Caruso I
Gut; 1996 Jul; 39(1):22-6. PubMed ID: 8881802
[TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
Brereton N; Winn B; Akehurst R
J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652
[TBL] [Abstract][Full Text] [Related]
40. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
